A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Decitabine (Primary) ; NTBI 1301 (Primary) ; NTBI 1301 (Primary) ; Aldesleukin; Cyclophosphamide
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 05 Oct 2017 Planned initiation date changed from 30 Sep 2017 to 30 Oct 2017.
- 05 Sep 2017 Planned initiation date changed from 31 Aug 2017 to 30 Sep 2017.
- 07 Aug 2017 Planned initiation date changed from 31 Jul 2017 to 31 Aug 2017.